drug

JANX014

1 story · latest Aug 6, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Janux Therapeutics

Timeline

Janux reports Q2 2026 results, keeps prostate cancer and autoimmune programs on track

Aug 6Quarterly updateJanux Therapeutics JANX007

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.